As part of our tiered CDMO framework spanning Pharmaceutical Development & Manufacturing and Biosimilar Development, we deliver end-to-end, laboratory-centered programs for EPO biosimilars. Our work emphasizes phase-appropriate chemistry, manufacturing, and controls (CMC) and rigorous analytical similarity to enable the reliable progression of development assets.
Overview of Erythropoietin (EPO) Biosimilar
Erythropoietin is a glycoprotein growth factor produced recombinantly in mammalian systems and characterized by multiple N-linked glycosylation sites that critically influence activity, exposure, and charge heterogeneity. As a reference-guided protein with well-defined critical quality attributes (CQAs), EPO is among the most analytically challenging biosimilars because minor shifts in glycan composition, sialylation, and terminal linkages can affect bioactivity readouts and stability profiles. Robust biosimilar programs, therefore, hinge on precise control of cell line selection, process parameters that tune glycosylation, and multi-modal orthogonal analytics that deconvolute structure–function relationships. Moreover, sound comparability strategy, forced-degradation mapping, and potency alignment across in-vitro assays collectively support high-fidelity EPO biosimilar development under a modern CMC paradigm.
Our Services
Our scope spans analytical similarity planning, mammalian upstream–downstream process development, biosimilar-focused characterization, stability and formulation science for development supply.
Analytical Similarity Strategy Service
We design and execute an EPO-specific analytical similarity plan mapped to the reference product's quality attributes. Workstreams include CQA risk ranking, attribute target setting, method selection/qualification, and data acceptance criteria. Techniques encompass intact/reduced LC-MS, peptide mapping, released N-glycan profiling, sialic acid quantitation, icIEF/CE-SDS, RP/SEC/HIC chromatography, glycopeptide analytics, and cell-based potency with complementary receptor-proximal readouts.
Mammalian Cell Line & Upstream Development Service
We establish CHO-based production lines with emphasis on glycoform consistency and productivity. Activities include vector design to preserve native signal peptide and pro-sequence, clonal screening with high-throughput glycan fingerprints, media/feed design to modulate galactosylation and sialylation, and scale-down models that capture oxygenation, osmolality, and trace metal effects on charge variants. Fed-batch or perfusion strategies are selected to balance titer, quality, and scalability.
Downstream Purification & Glycoform Control Service
We configure purification trains to maintain EPO integrity and desired isoform distribution. Unit operations typically include capture chromatography, polishing steps for host-cell proteins/DNA, and charge-based fractionation to refine isoforms. Process parameters (pH, conductivity, temperature, residence time) are engineered to minimize desialylation and oxidation while preserving potency. Viral clearance unit operations are integrated in alignment with phase-appropriate expectations.
Potency & Bioassay Lifecycle Management Service
We develop statistically robust cell-based potency methods aligned to EPO's mechanism of receptor engagement and downstream signaling. The bioassay lifecycle spans feasibility, optimization, validation-readiness, and ongoing monitoring. We harmonize cell-based results with physicochemical surrogates (e.g., receptor binding) to strengthen the totality of evidence and manage assay drift through reference standard control strategies.
Stability & Formulation Development Service
We engineer formulation systems to protect the glycoprotein against deamidation, oxidation, aggregation, and desialylation. Work includes buffer screening, excipient compatibility, surfactant and antioxidant optimization, and device-material extractables/leachables risk assessments for development packs. Forced-degradation studies establish stability-indicating methods; real-time and accelerated programs define shelf-life projections for development materials.
Biosimilar Comparability & Reference Product Bridging Service
We source and qualify multiple lots of the reference product to map attribute ranges and lot-to-lot variability. Bridging designs link early-phase materials to later-phase processes via tiered comparability, leveraging orthogonal analytics and potency mapping. Data packages are assembled to align with biosimilar guidelines while staying focused on laboratory evidence and CMC coherence.
We deliver EPO biosimilar programs that combine similarity-driven analytics, glycoform-aware process design, and formulation science. Engage our team to accelerate development with rigorous laboratory execution and a cohesive biosimilar strategy.
Frequently Asked Questions
Q1: What are the most critical CQAs for an EPO biosimilar, and how are they controlled?
Key CQAs include glycan composition (branching, sialylation, fucosylation), charge heterogeneity, purity/aggregates, sequence integrity, oxidation/deamidation, and potency. Control is achieved through CHO clone selection, media/feed optimization, precise upstream parameters, gentle downstream processing, and comprehensive analytical monitoring (e.g., released N-glycans, icIEF, CE-SDS, SEC, LC-MS, and validated cell-based potency).
Q2: How is glycosylation tuned during development without compromising productivity?
Glycosylation is tuned by modulating culture conditions (nutrients, osmolality, dissolved oxygen, trace elements) and feed strategies that influence galactosyltransferase and sialyltransferase activity. Parallel clone panels and scale-down bioreactors provide glycan-quality maps that guide selection. Downstream polishing and charge-fractionation steps further refine isoform distributions while maintaining yield.
Q3: What stability risks are most common for EPO, and how does formulation mitigate them?
Common risks include aggregation, oxidation (e.g., methionine), deamidation, and loss of sialic acids. Formulation mitigations include optimized pH buffering, compatible excipients, surfactants to manage interfaces, antioxidants where appropriate, and low-stress processing. Forced-degradation studies identify dominant pathways, enabling selection of conditions that preserve activity throughout intended storage.
Our products and services are for research use only.
